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Since its initial identification in St. Petersburg, Russia, the recombinant hepatitis C virus (HCV) 2k/1b has been isolated from
several countries throughout Eurasia. The 2k/1b strain is the only recombinant HCV to have spread widely, raising questions
about the epidemiological background in which it first appeared. In order to further understand the circumstances by which
HCV recombinants might be formed and spread, we estimated the date of the recombination event that generated the 2k/1b
strain using a Bayesian phylogenetic approach. Our study incorporates newly isolated 2k/1b strains from Amsterdam, The Neth-
erlands, and has employed a hierarchical Bayesian framework to combine information from different genomic regions. We esti-
mate that 2k/1b originated sometime between 1923 and 1956, substantially before the first detection of the strain in 1999. The
timescale and the geographic spread of 2k/1b suggest that it originated in the former Soviet Union at about the time that the
world’s first centralized national blood transfusion and storage service was being established. We also reconstructed the epi-
demic history of 2k/1b using coalescent theory-based methods, matching patterns previously reported for other epidemic HCV
subtypes. This study demonstrates the practicality of jointly estimating dates of recombination from flanking regions of the
breakpoint and further illustrates that rare genetic-exchange events can be particularly informative about the underlying epide-
miological processes.
Hepatitis C virus (HCV) infection presents a major globalhealth burden, with the WHO estimating that 170 million
chronic carriers are at risk of developing severe clinical outcomes
such as cirrhosis and hepatic cellular carcinoma (56, 71). The virus
belongs to the single-stranded positive-sense RNA virus family
Flaviviridae and is characterized by considerable genetic diversity.
HCVdiversity is classified into sixmain genotypes (genotypes 1 to
6), each of which is further divided into numerous subtypes, and
the virus exhibits nucleotide sequence divergences of 30 and 20%
at the genotype and subtype levels, respectively (58). The high
genomic heterogeneity of HCV is a result of both its high rate of
evolution and its long-term association with human populations
(60). Although there is no indication for a zoonotic virus reser-
voir, a related virus has recently been discovered in dogs (22).
The greatest diversity of HCV is found in West and Central
Africa and in Southeast Asia, where the virus appears to have
persisted endemically for at least several centuries (49, 60). The
current distribution of HCV genotypes and subtypes is geograph-
ically structured, reflecting differences in the rates and routes of
transmission of the various subtypes and genotypes. Epidemic
strains, exemplified by subtypes 1a, 1b, and 3a, are characterized
by high prevalence, low genetic diversity, and a global distribution
and are typically associated with transmission via infected blood
products and injecting drug use (IDU) during the 20th century
(13, 44–46, 54, 57). In contrast, endemic strains aremore spatially
restricted but harbor greater genetic diversity than epidemic
strains, and it is currently thought that this endemic diversity pro-
vided the source of the epidemic strains that constitute themajor-
ity of HCV infections worldwide (47, 60).
Recombination is thought to play a comparatively minor
role in shaping the genetic diversity of HCV; however, an in-
creasing number of reports suggests that it is not entirely insig-
nificant in HCV evolution. Most notable of these was the initial
discovery of a natural recombinant form of HCV circulating in
injecting drug users resident in St. Petersburg, Russia (20). This
recombinant, labeled 2k/1b, has a 5= genome region that is
most closely related to subtype 2k and a 3= genome region that
is most closely related to the global epidemic subtype 1b, with a
single recombination breakpoint located at genomic position
3175 or 3176 in the NS2 gene (20). Since the discovery of 2k/1b,
several other studies have reported both inter- and intrageno-
typic HCV recombinants in natural populations, although the
evidence presented for recombination varies in strength; the
weakest studies report only discordant genotyping results be-
tween genome regions (which could also result from coinfec-
tion), whereas the most convincing studies repeatedly se-
quence the same recombination breakpoint from independent
extractions (thereby excluding the possibility of in vitro genetic
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exchange). Thus far there have been nine descriptions of HCV
recombinant forms, although only in six cases have the break-
points been sequenced (6–8, 19, 28, 29, 42).
Inspection of the recombination breakpoint positions within
the HCV genome reveals a difference between inter- and intra-
genotypic recombinants. Breakpoints in the intrasubtypic recom-
binants (1a/1c and 1b/1a) are located in the E1/E2 region, while in
the intergenotypic recombinants (including 2k/1b), the break-
points are consistently found in theNS2-NS3 region (8, 19, 28, 29,
39, 42). Interestingly, naturally occurring intergenotypic HCV re-
combinants have more often than not involved genotype 2 in the
5= genome region (19, 20, 28, 29, 42). This may reflect some in-
herent yet unknown biological or ecological properties of this ge-
notype to produce viable recombinant viruses.
Nevertheless, the low rate of discovery of novel recombinant
forms suggests that although recombination does occur inHCV, it
is an uncommon event, at least in comparison to HIV-1. Indeed,
the 2k/1b strain discovered in St. Petersburg is the only known
circulating recombinant form (CRF) of HCV and has therefore
been designated CRF01_1b2k, following a naming scheme similar
to that developed forHIV-1 recombinants (23). ACRF is a recom-
binant form that is found repeatedly in different patients. Since its
discovery, CRF01_1b2k has been isolated from patients in many
countries, including Ireland, France, Cyprus, Azerbaijan, Uzbeki-
stan, and Russia (20, 25, 26, 29, 37–39). CRF01_1b2k is the only
recombinant strain of HCV to have transmitted widely; therefore,
it is important to investigate its genesis and dissemination in order
to understand why it might be unique and to evaluate the likeli-
hood that other HCV recombinant forms could increase in prev-
alence in the future.
Evolutionary analysis of viral genomes usingmethods based on
molecular clocks and coalescent theory has previously proved use-
ful in reconstructing the epidemic history of various HCV strains,
including subtypes 1a and 1b worldwide (33, 46) and subtype 1b
in Japan (66). Similar analyses of HCV genotype 4 in Egypt have
estimated the timescale of the largeHCV epidemic in that country
and have confirmed its iatrogenic cause (48, 65). Very little is
known about the evolutionary history of HCV subtype 2k, most
likely because of the lack of sequence data for the strain.
In order to address the lack of information about the epidemi-
ological and transmission history of HCV CRF01_1b2k, we have
conducted a comprehensive evolutionary analysis of all available
viral genome sequences using a well-established Bayesian frame-
work (11). Since previously published sequence data on
CRF01_1b2k are limited, we sought to increase the sample size by
isolating and sequencing a panel of new recombinant isolates
frompatients of Russian origin resident in Amsterdam, TheNeth-
erlands.
By combining information fromdifferent genomic regions in a
single analysis, we provide the first estimate of the date of the
recombination event that generated CRF01_1b2k. The date that
we obtained considerably predates the discovery of the strain and
requires a reevaluation of the circumstances surrounding its ori-
gin. This is the first time that a recombination event has been
dated for any virus other than HIV-1 (32, 51, 67) or influenza A
virus (27). Further, we estimate the CRF’s past rate of transmis-
sion and its pattern of global geographic spread. To obtain more
precise parameter estimates when dating recombination events,
we employed a joint phylogenetic approach that improves on
methods previously applied toHIV-1CRFs (51, 67). Themethods
introduced here should serve as a model for future phylogenetic
investigations of genetic-exchange events in RNA virus popula-
tions.
MATERIALS AND METHODS
Identification and sequencing of newHCV2k/1b isolates fromAmster-
dam. In the course of a study of HCV-infected patients resident in Am-
sterdam (unpublished data), it was found that HCV genotyping results
from the 5= untranslated and NS5B regions were discordant for 6 (out of
200) patients. Of these, five weremale and onewas female, and theirmean
age was 34 years (Table 1). For this study, the 5=-end sequences were not
used.
HCV RNA was isolated from 200 l plasma using the purification
method described by Boom et al. (4). cDNA was generated using random
hexamer primers as described before (4). The amplification was per-
formed using a conventional PCRwith the following cycling conditions: 2
min at 50°C and 10 min at 95°C, followed by 45 cycles, each consisting of
30 s at 95°C, 30 s at 55°C, and 1 min at 72°C. Amplicons were purified
from a 1% agarose gel as described by Boom et al. (4). Amplification of a
724-nucleotide (nt) fragment (unpublished data) of the NS5B region was
performed as previously described (40). Amplification of core/E1 was
performed in a 25-l volume using HCV1b/2 F (GCGTGAGRGTCCTG
GAG) as the forward primer and HCV1b/2 R (TGCCARCARTANGGCY
TCAT) (positions 292 to 312; all primer locations are indicated relative to
the H77 reference genome) as the reverse primer, using the same ampli-
fication conditions mentioned above. Amplicons were also purified from
a 1% agarose gel as described by Boom et al. (4). Sequencing was per-
formed using HCV1b/2F seq (CTTCYTACTAGCTCTYTTGTCTT; posi-
tions 128 to 112) as the forward sequencing primer and HCV1b/2R seq
(TGCCAACTGCCRTTGGTGT; positions 2386 to 2410) as the reverse
sequencing primer.
To confirm that the viral variants were recombinants, a 234-nt frag-
ment harboring the known breakpoint in NS2 was also amplified and
sequenced. Amplification and sequencing of the NS2 breakpoint were
performed using HCV2K_F (GCACGCCATACTTCGTCAGAG) as the
forward primer and HCV1B_R (CAGGTAATGATCTTGGTCTCCA
TGT) as the reverse primer, also using the same cycling conditions men-
tioned above.
In addition to new CRF01_1b2k sequences from Amsterdam, 6 re-
combinant isolates from an unpublished study were also included. These
sequences were sampled from IDUs in Azerbaijan (Table 1). Most of the
remaining CRF01_1b2k isolates came from a study of IDUs inUzbekistan
(25) and from a cohort study of HCV-positive patients from seven coun-
tries (26); detailed demographic information on isolates from these two
studies is provided here (Table 1). In the latter study, all individuals in-
fected with CRF01_1b2k came from either Russia or Uzbekistan, and 6 of
these patients were linked to high-risk groups, namely, blood transfusion
recipients or intravenous drug users.
CollationofHCVsequence alignments.To investigate the evolution-
ary origin and spread of HCV CRF01_1b2k, a data set comprising all
subtype 2k/1b (n 27), 2k (n 15), and 1b (n 71) isolates for which
both core/E1 and NS5B sequences were available was collated from
GenBank and the HCV Sequence Database (24) (see Table S1 in the sup-
plemental material). This collection included the 6 newly sequenced iso-
lates obtained fromHCV patients in Amsterdam (see above). Alignments
for both genome regions were constructed manually, and each alignment
contained exactly the same set of taxa. The date and sampling location of
each sequence were obtained from the literature or via personal commu-
nication (Table 1).
Estimation of genome region-specific rates of evolution. The evolu-
tionary rates of the core/E1 andNS5B regions used in this study could not
be estimated directly from our data, because the sample size and range of
sample dates were not large or wide enough. In line with previous studies
of HCV epidemic history (e.g., see reference 48), we employed an inde-
pendent data set with significant temporal information to provide the
Origin and Evolution of HCV 2k/1b
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substitution rates of the subgenomic regions of interest. Specifically, we
used the data and analysis strategy of a recent study that reported rates of
evolution for all HCV genome regions for subtypes 1a and 1b (14). That
study utilized an alignment-partition approach, which was implemented
in the BEAST program, to estimate region-specific rates (11). We applied
a codon-structured nucleotide substitution model (55), an uncorrelated
relaxed lognormalmolecular clock (10), and a Bayesian skyline coalescent
model (12) to both subtype 1a and 1b whole-genome alignments, from
which we obtained rate estimates for the precise subgenomic regions
(core/E1 and NS5B) used in our analysis of CRF01_1b2k. The Markov
chainMonteCarlo chains (MCMCs)were run for 200million generations
and sampled regularly to yield a posterior tree distribution based upon
10,000 estimates. For further analysis details, see reference 14.
Phylogenetic analysis. Preliminary phylogenetic analyses were un-
dertaken to confirm that CRF01_1b2k originated from a single recombi-
nation event. Neighbor-joining (NJ) trees of the core/E1 and NS5B data
sets were estimated using the PAUP* program (64) with an HKY85 nu-
cleotide substitution model and a gamma distributed among site rate
heterogeneity (data not shown).
Next, in order to directly test the hypothesis of a single recombinant
origin, we performed Bayesian MCMC analysis of the core/E1 and NS5B
data sets in two ways: (i) we constrained the CRF01_1b2k isolates to be a
monophyletic clade, and (ii) no phylogenetic constraints were imposed.
The hypothesis of a single origin was then tested by performing a Bayes
factor (BF) comparison of the marginal likelihoods (41, 63) obtained
from these two analyses. This revealed an insignificant difference between
the two competing hypotheses; thus, a single recombination event was
assumed in following analyses.
Molecular clock analysis. In order to estimate the date of the recom-
bination event that formed CRF01_1b2k, we created separate data sets for
the core/E1 and NS5B regions that contained the CRF isolates, plus all
available closely related parental subtype reference sequences (belonging
to subtype 2k for the core/E1 region and to subtype 1b for the NS5B
region). A hierarchical phylogeneticmodel (62)was used to combine both
data sets and thereby provide a joint estimate of the time to the most
recent common ancestor (TMRCA) of the CRF clade, while accounting
for uncertainty in both genome regions.
As theCRF clade in the different genome regions is known to represent
a common evolutionary history, jointly estimating the age of this clade
will maximize the explanatory power of the data (62) and is thus more
powerful than analyzing the regions independently, as has been done pre-
viously (e.g., see reference 67). However, due to the recombination of the
different subtypes, we cannot simply assume that a single tree represents
the entire genome. Instead, we allow independent trees for each genomic
region but maintain the TMRCA of the CRF clade in each region to lie
within a small time of each other, while estimating themean of these as the
parameter of interest.
Specifically, separate phylogenies, molecular clock models, and sub-
stitution models were estimated for the core/E1 and NS5B regions. The
genome region-specific rates (estimated as described above) were used as
prior distributions for the evolutionary rates for the core/E1 and NS5B
regions. For the NS5B region, the rates estimated from subtype 1b were
applied, while for the core/E1 region, the average of the 1a and 1b rateswas
used (because a subtype 2k-specific rate was not available).
For each pair of sampled phylogenies (core/E1 and NS5B) in the pos-
terior distribution of the MCMC, three node dates were obtained (as
labeled in Fig. 2): A, the joint TMRCA of the CRF clade; B, the date of the
parental node of the CRF clade in the core/E1 subtype 2k phylogeny; and
C, the date of the parental node of the CRF clade in the NS5B subtype 1b
phylogeny. The former date, together with the more recent of the last two
TABLE 1 Epidemiological and sequence information of the CRF01_1b2k isolates used in this studya
Isolate name
Age
(yr)
Gender
Sampling
location
Risk
factor(s)
Country of
origin
GenBank accession no.
NS2
breakpoint
Reference or
sourceNS5B
Core/E1
accession
1b2k_AZ_01AZ051_2000 34 M Azerbaijan IDU Azerbaijan FJ435529 FJ435462 NA Unpublished
1b2k_AZ_01AZ082_2000 38 M Azerbaijan IDU Azerbaijan FJ435544 FJ435480 NA Unpublished
1b2k_AZ_02AZ105_2001 32 M Azerbaijan IDU Azerbaijan FJ435550 FJ435490 NA Unpublished
1b2k_AZ_02AZ114_2001 41 M Azerbaijan IDU Azerbaijan FJ435556 FJ435497 NA Unpublished
1b2k_AZ_02AZ129_2001 30 M Azerbaijan IDU Azerbaijan FJ435564 FJ435505 NA Unpublished
1b2k_AZ_02AZ139_2001 33 M Azerbaijan IDU Azerbaijan FJ435572 FJ435514 NA Unpublished
1b2k_CY_CYHCV037_2005 NA NA Cyprus ST/IDU Georgia EU684614 EU684686 NA 9
1b2k_CY_CYHCV093_2007 NA NA Cyprus ST/IDU Georgia EU684649 EU684728 NA 9
1b2k_AM_P077_2006 35 M Amsterdam IDU Russia JF949902 JF949908 Confirmed This study
1b2k_AM_P079_2006 42 M Amsterdam NA Georgia JF949897 JF949903 Confirmed This study
1b2k_AM_P108_2007 35 M Amsterdam IDU Georgia JF949898 JF949904 Confirmed This study
1b2k_AM_P135_2005 35 F Amsterdam NA Georgia JF949899 JF949905 Confirmed This study
1b2k_AM_P159_2007 39 M Amsterdam NA Georgia JF949900 JF949906 Confirmed This study
1b2k_AM_P179_2000 21 M Amsterdam IDU Georgia JF949901 JF949907 Confirmed This study
1b2k_FR_M21_2007 30 M France IDU Georgia FJ821465 FJ821465 Confirmed 38
1b2k_IE_HC9A99966_2006 NA NA Ireland NA Russia AB327058 AB327018 Confirmed 37
1b2k_RU_747_1999 NA NA Russia IDU Russia AF388411 AY070214 Confirmed 20, 21
1b2k_RU_796_1999 NA NA Russia NA Russia AF388412 AY070215 Confirmed 20, 21
1b2k_RU_ALT30_2000 34 F Russia NA Russia AB327055 AB327015 Confirmed 26
1b2k_RU_HIA1002_2003 NA NA Russia NA Russia DQ001221 AB327011 Confirmed 26
1b2k_RU_KNG318_2002 30 M Russia IDU Russia AY764172 AB327010 Confirmed 26
1b2k_RU_KNG327_2002 25 M Russia NA Russia AY764176 AB327012 Confirmed 26
1b2k_RU_N687_1999 NA NA Russia NA Russia AY587845 AY587845 Confirmed 26
1b2k_RU_PSA108_2005 37 M Russia NA Russia AB327053 AB327013 Confirmed 26
1b2k_RU_PSA62_2005 50 M Russia BT Russia AB327054 AB327014 Confirmed 26
1b2k_UZ_AZ15 22 M Uzbekistan BT/IDU Uzbekistan AB327056 AB327016 Confirmed 25
1b2k_UZ_UZIDU19_2006 NA NA Uzbekistan IDU Uzbekistan AB327120 AB327122 Confirmed 25
a M, male; F, female; NA, not available; IDU, intravenous drug usage; BT, blood transfusion; ST, sexual transmission.
Raghwani et al.
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dates, therefore defines a time range during which the recombination
event must have occurred (see Fig. 2). The posterior distribution of this
time range was then compiled by repeating the above-described proce-
dure for each pair of phylogenies in theMCMC output. The BEAST anal-
ysis model settings were the same as those outlined in the section on
genome region-specific rates above.
CRF01_1b2k transmission history. Further Bayesian MCMC phylo-
genetic analyses were performed solely on the CRF01_1b2k isolates in
order to estimate the epidemic history and basic reproductive number,R0,
of the strain since its emergence. BEAST model settings were the same as
those outlined above, except that different coalescent models were em-
ployed to reconstruct the transmission history of the CRF. Both the
GMRF skyride (36) and exponential-growth coalescentmodelswere used.
RESULTS
Estimation of genome region-specific rates of evolution. The
rates of evolution of the core/E1 and NS5B genomic regions used
in this study were estimated from subtype 1a and 1b whole-
genome data sets (see Materials and Methods) and are given in
Table 2. The rates for the NS5B region corresponded between
subtypes, with similar 95%highest posterior density (HPD) inter-
vals, while the rate estimates for the core/E1 region did show some
variation among subtypes (Table 2).
Phylogenetic analysis.To establish the evolutionary origins of
the HCV 2k/1b strain, we analyzed the core/E1 (644 nt) andNS5B
(741nt) regions of 27CRF1b/2k, 15 subtype 2k, and 71 subtype 1b
isolates. The 2k/1b isolates were sampled between 1999 and 2007
and were from the following locations: Ireland, Uzbekistan, Azer-
baijan, Cyprus, Amsterdam, France, and Russia (Table 1). Since
the BF test supported the hypothesis that the 2k/1b isolates were
monophyletic, a single origin of the CRF was inferred (BFs for the
comparisons ofmonophyly and nonmonophylymodels were 0.31
for the core/E1 data set and0.68 for theNS5B data set). Further-
more, the monophyletic origin of the CRF clade was supported in
both genome regions when no phylogenetic constraints were im-
posed. However, monophyly of CRF 1b/2k isolates was not sup-
ported by a high posterior probability (0.67) in the NS5B maxi-
mum clade credibility (MCC) tree, most likely reflecting the
uncertainty associated with the star-like phylogeny and relatively
short sequence length. However, the recombinant nature of many
of the isolates in this study was confirmed by direct observation of
the breakpoint in the NS2 gene region (confirmed isolates are
represented by filled circles in Fig. 1).
Molecular clock analysis. Figure 1 and Table 3 provide the
estimated TMRCAs of the CRF clade obtained using the joint and
independent molecular clock analyses. The estimates obtained
separately from the core/E1 and NS5B data sets were in close
agreement and exhibit overlapping 95%HPD intervals. These es-
timates also agree with the joint estimate of TMRCA of the CRF
(node A), which was 1946 (1932 to 1959; Table 3). We also esti-
mated the date of the most recent common ancestor of the CRF
clade and its most closely related parental isolate (Fig. 2). These
estimates were again similar for both genome regions, at about
1933 (Table 3). Lastly, by comparing the HPDs of the node A date
with the dates of themore recent of the two parental nodes (either
B or C), we were able to generate bounds for the time of the
TABLE 2 Evolutionary rate estimates of the genomic regions used in
this study
Genomic region
No. of substitutions/site/yr (103)a
HCV subtype 1a HCV subtype 1b Average rate
Core/E1 1.75 (1.41, 2.10) 1.36 (1.01, 1.76) 1.56 (1.21, 1.93)
NS5B 0.89 (0.71, 1.07) 0.91 (0.68, 1.14) 0.90 (0.70, 1.11)
a The estimates were obtained from HCV subtype 1a and 1b whole genomes using a
genomic partition model (see Materials and Methods). The numbers inside parentheses
represents the 95% highest posterior density credibility interval.
FIG 1 Molecular clock phylogenies of CRF01_1b2k and its parental subtypes, estimated from the core/E1 alignment and the NS5B alignment. The horizontal
bars in each phylogeny contain the dating estimates for two nodes: the common ancestor of the CRF clade (1931 or 1932 to 1958) and the common ancestor of
the CRF and the most closely related parental strain (1910 to 1912 to 1952 or 1953). Filled circles, 2k/1b isolates that were confirmed as being recombinant by
sequencing of the breakpoint in the NS2 region; open circles, those isolates for which NS2 sequences were not available. The trees shown are themaximum clade
credibility trees from the Bayesian MCMC analysis.
Origin and Evolution of HCV 2k/1b
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recombination event that generated the CRF, which was between
1923 and 1956.
CRF01_1b2k transmission history. Figure 3 shows the esti-
mated epidemic history of CRF01_1b2k, as estimated using the
Bayesian skyride plot method, which depicts the effective popula-
tion size of the CRF epidemic over time. The plot indicates ap-
proximately constant exponential growth since the emergence of
the CRF lineage (Fig. 3) until the mid-1990s, after which the ef-
fective population size declines or stabilizes (either is plausible,
given the size of the credible region of the estimate). This decrease/
stabilization coincides with the advent of screening for HCV in
blood donors, which greatly reduced the risk of HCV infection via
blood transfusion (31, 52, 70).
To ascertain the CRF’s exponential growth rate (r), the CRF
data set was also analyzed using an exponential-growth coalescent
model. The estimated growth rate was 0.116 year1 (95% HPD
interval, 0.079 to 0.159). This estimate was subsequently used to
calculate R0 values for the CRF01_1b2k strain under a plausible
range of average durations of infectiousness (D), using the equa-
tion R0  rD  1 (46). Both the estimated growth rate (r  0.1
year1) and the estimated R0 values (R0,2 to 4) are compatible
with a number of equivalent estimates for other HCV subtypes,
including those from IDU risk groups (46–48, 66).
The MCC tree of the CRF01_1b2k clade (Fig. 4), when com-
bined with all available epidemiological information (Table 1),
indicates a clear pattern of phylogenetic clustering according to
the geographic location and risk factor of each patient. For exam-
ple, where these details were available, 14 out of 15 isolates were
associated with IDU, while only 1 was isolated from a patient with
a history of blood transfusion (Table 1). These observations fur-
ther support the view that CRF01_1b2k transmission is strongly
linked with the IDU transmission route. Although it is not possi-
ble to reconstruct the location of the common ancestor of the CRF
lineagewith any certainty (because our sample size is small and the
basal branches of the phylogeny are poorly supported), all of the
isolates included in this study are from or have an epidemiological
link to the former Soviet Union, and the oldest strain was sampled
in Russia in 1999. A well-supported cluster of strains from Azer-
baijan originated in about 1970, and therefore, the CRF has likely
circulated there since that time. Hence, it appears that
CRF01_1b2k disseminated throughout the Soviet Union before
its dissolution in the late 1980s and for some time prior to the
discovery of the CRF in St. Petersburg in 1999.
DISCUSSION
As the only known HCV recombinant in widespread circula-
tion, the existence and emergence of CRF01_1b2k present an
interesting question in HCV epidemiology and evolution. In-
vestigating its evolutionary origins and transmission history
helps to understand the circumstances that led to its unique
properties. In contrast to HIV, which has 49 known CRFs and
a much greater number of unique recombinant forms (30),
recombination typically contributes little to the generation and
maintenance of HCV genetic diversity. Given that HCV has a
higher global prevalence than HIV and, thus, all else being
equal, there is a high likelihood of dual infections with diver-
gent HCV strains, it is unlikely that epidemiological factors are
TABLE 3 Estimates of TMRCA of the CRF clade obtained from separate genome regions and from joint (hierarchical) phylogenetic analysis
Clade (nodea)
TMRCA (yr)b
Core/E1 NS5B Joint (hierarchical) estimate
CRF (A) 1945.2 (1931.6, 1958.3) 1945.8 (1932.4, 1958.5) 1946.0 (1932.5, 1959.0)
CRF 2k (B) 1932.0 (1909.7, 1952.8) NA NA
CRF 1b (C) NA 1933.1 (1912.0, 1952.1) NA
a The node labels highlighted in Fig. 2.
b The numbers inside parentheses represent the 95% highest posterior density credibility interval. NA, not available.
FIG 2 An illustration to explain the structure of the joint phylogenetic method that we employed to estimate the date of the recombination event that generated
CRF01_1b2k. The core/E1 tree is shown on the left and the NS5b tree on the right; in both, the shaded box highlights the CRF01_1b2k clade. The left axis depicts
the time of the ancestral nodes (node B in the core/E1 tree and node C in the NS5B tree). The right axis shows the TMRCA of CRF01_1b2k (node A). Both CRF
node A (estimated jointly from the core/E1 andNS5B regions) and the youngest parental node (either B or C) were used to calculate theminimum time window
for the recombination event to have occurred.
Raghwani et al.
2216 jvi.asm.org Journal of Virology
 o
n
 M
ay 2, 2013 by VRIJE UNIVERSITEIT
http://jvi.asm.org/
D
ow
nloaded from
 
restricting the opportunities for HCV to generate CRFs. Mixed
infections with divergent HCV strains have been reported for
many different populations and are noted to be prevalent
among high-risk groups, particularly IDUs and some hemo-
philiacs (3, 5, 16, 50, 53).
Since the opportunities for HCV recombination are not lim-
ited, it is more likely that fundamental molecular and evolution-
ary differences betweenHIV andHCV explain whyHIV hasmany
CRFs andHCVhas few. These could include differences in the rate
of template switching or differences in genomic or immunological
constraints, such that HCV recombinants have, on average, lower
fitness than HIV recombinants and therefore are rarely transmit-
ted (72). Although both viruses are associated with chronic infec-
tions, unlike HIV, HCV can be spontaneously cleared by the host.
This may explain in part the differences in the number of recom-
binants between HIV and HCV, where partial protective immu-
nity against the latter reduces that chance of in vivo recombination
of HCV strains (1, 43, 69). However, the high rate of mixed infec-
tions observed suggests that this is likely at best to play a minor
role in HCV recombination. The low frequency of HCV recom-
binants is more likely to reflect mechanistic constraints on viral
replication. There is evidence that template switching in HCV is
FIG 3 Estimated Bayesian skyride plot of the CRF01_1b2k clade. The vertical
axis represents the product of viral generation time and the effective number of
infections (Ne). The solid line shows the best estimate, and the shaded area
shows the 95% credible region of this estimate.
FIG 4 Molecular clock phylogeny of the CRF01_1b2k clade, estimated using a relaxed uncorrelated lognormal clock model and the SDR06 nucleotide
substitutionmodel (seeMaterials andMethods). Sequences are color labeled according to the country of origin (diamonds) and the country of sampling (circles).
All isolates were found to have an epidemiological link to Russia or the former SovietUnion (Table 1). Filled circles/diamonds, 2k/1b isolates that were confirmed
as being recombinant by sequencing of the breakpoint in the NS2 region; open circles/diamonds, those isolates for which NS2 sequences were not available. The
numbers above the branches show the posterior probability of nodes in the MCC tree; numbers below the branches represent bootstrap support values using
maximum likelihood.
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especially rare and that the replication complex is typically en-
coded on the same genomic strand that it will replicate and tran-
scribe (2). It is also interesting that when replication complexes
are exchanged between different genotypes, the replication effi-
ciency is substantially reduced (15). The pseudodiploidy of the
HIV genome certainly increases the likelihood of recombination
occurring due to the ability of the virus to package two RNA tem-
plates (17), while the secondary RNA structure in the HCV ge-
nome may limit the production of viable hybrid HCVs (59, 68).
Our study of previously reported and newly obtained HCV
isolates provides the first estimates of the date of the recombina-
tion event that generated CRF01_1b2k. We estimated the time of
origin of CRF01_1b2k to be between 1923 and 1956, which is not
much later than the origin and global spread of the parental sub-
type 1b (33). This date is significantly earlier than we expected: we
expected that the CRF’s creation might be linked to the dramatic
increase in IDU behavior following the breakup of the former
Soviet Union. This result is robust to the manner of isolate sam-
pling: if, because of nonrandom sampling, our isolates are more
closely related to each other than under random sampling, then
the TMRCA of CRF01_1b2k would be biased toward more recent
dates. Furthermore, despite its small size, our data set provides a
relatively short time window during which the recombinant must
have arisen (Fig. 2). The involvement of subtype 1b in the recom-
binant is not surprising, as it is one of themost prevalent subtypes
worldwide. However, to fully appreciate the origin of CRF01_1b2k,
we need to consider the evolutionary history of both parental sub-
types and of the recombinant lineage itself. Genotype 2 harbors con-
siderable genetic diversity, especially in West Africa, which is where
the genotype is thought to have originated (34). Although the small
number of subtype 2k isolates sampled to date likely underestimates
the true extent of subtype 2k distribution, such viruses have been
isolated fromMartinique andMadagascar, implicating a role for the
historical trans-Atlantic slave trade in the dissemination of the virus
fromWest Africa (34).
The current distribution of subtype 2k is associated with fran-
cophone regions and former Soviet Union countries. In contrast,
CRF01_1b2k is more spatially limited, with all isolates being di-
rectly or indirectly linked to the former Soviet Union. As the non-
recombinant subtype 2k isolates that are most closely related to
CRF01_1b2k are fromMoldova and Azerbaijan (see Fig. S1 in the
supplementalmaterial), it seemsmost likely thatCRF01_1b2kwas
generated in the former Soviet Union. An equivalent analysis of
subtype 1b viruses provides no reliable phylogeographic linkage,
due to the low phylogenetic resolution of the NS5B data set.
Our estimated date of CRF origin coincides with an interesting
period of history in the former Soviet Union, which was an early
leader in transfusion technology. Under the leadership of Alexan-
der Bogdanov in the 1920s, a nationwide network of blood trans-
fusion centers and research institutes, as well as the Central Insti-
tute of Hematology in Moscow, Russia, in 1926, was established
throughout the Soviet republics (61). This expanded into a net-
work of1,500 blood donating centers across the republics (18).
The Soviets also adopted blood storage and preservation tech-
niques at an early stage. They established more than 60 primary
and 500 subsidiary blood storage centers by the mid-1930s, which
shipped blood across the entire Soviet Union (61). During the
SecondWorldWar, these networks were swiftly readapted to sup-
port the front line; inMoscow alone, about 2,000 blood donations
were given per day (18, 61). The impressive scale of the blood
service in the former Soviet Union is likely to have favored HCV
transmission by increasing the efficiency and geographic range of
the virus’s dissemination. Whether specific medical practices at
this time increased the probability of mixed viral infections re-
mains unknown. It is interesting to note that Bogdanov himself
was fascinated by the ideological interpretation of blood sharing
and frequently practiced what he called “physiological collectiv-
ism”: the exchange of blood with others through mutual transfu-
sions (61).
Although unscreened blood transfusions can provide a credi-
ble hypothesis for the origin of CRF01_1b2k in the Soviet Union
some time from 1923 to 1956, we must also attempt to explain
how subtype 2k or the CRF itself arrived in the Soviet Union from
WestAfrica or theCaribbean.Migration fromAfrica to the former
Soviet Union did occur during the late 1950s and 1970s as a result
of alliances forged by the Soviet government with newly indepen-
dent African states such as Ghana and Angola (35). However,
these connections are too late to have contributed to the emer-
gence of CRF01_1b2k, according to our dating estimates. Al-
though we cannot reject the hypothesis that the CRF was formed
in West Africa and subsequently moved to the Soviet Union, our
results are more consistent with the recombination event occur-
ring in the latter. This uncertainty is likely to be reduced with
further samples, especially subtype 2k viruses, from African and
former Soviet Union locations.
The epidemic history CRF01_1b2k (Fig. 3) since its emergence
is similar to that estimated for other epidemic subtypes of HCV
(e.g., see reference 33). The growth in the CRF01_1b2k effective
population sizes coincides with a substantial increase in blood
transfusion, including during the Second World War, and with
the subsequent rise in intravenous drug usage. CRF01_1b2k
transmission seems to have slowed or stabilized since the early
1990s, coinciding with the onset of the anti-HCV screening of
donors. In the absence of any data to the contrary, the transmis-
sion of this recombinant and its spread from the former Soviet
Union reflect the peculiar epidemiological properties of the risk
groups that it has been associated with rather than any intrinsic
properties of the virus.
We demonstrate the practicality and benefits of using a hierar-
chical phylogenetic model to jointly estimate parameters of inter-
est when analyzing multipartite sequence data that result from
genetic exchange. This method yields more accurate parameter
estimates than previous methods (e.g., see references 27 and 67)
by incorporating the phylogenetic information and uncertainty in
different genomic regions. We recommend that this improved
statistical framework be used in future investigations of recombi-
nation in fast-evolving RNA viruses.
This study has made significant steps in understanding the ep-
idemic history and spread of the unique circulating HCV recom-
binant 2k/1b. Most significantly, we show that this strain origi-
nated many decades before the post-Soviet rise in injection
behavior with which it is currently associated. On the basis of the
date of its origin and itsmolecular epidemiology, there are reason-
able grounds to suppose that the Soviet Union’s revolutionary
blood service was instrumental in the CRF’s early generation and
continental-scale spread. This infrastructure may have facilitated
the pan-Eurasian spread of other parenterally transmitted blood-
borne infections, and this is an interesting question for future
research.
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